Search research articles
Contact Us
Filters
Showing results (1161-1170 of 1,226) with videos related to
Page
of 123
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 1, 2014
Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials
Evguenia S Svarovskaia, Hadas Dvory-Sobol, Neil Parkin, et al.
Lancet (London, England)
|
March 19, 2013
Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial
Kris V Kowdley, Eric Lawitz, Israel Crespo, et al.
Cancer Prevention Research (Philadelphia, Pa.)
|
December 19, 2022
Phase I Trial of a Therapeutic DNA Vaccine for Preventing Hepatocellular Carcinoma from Chronic Hepatitis C Virus (HCV) Infection
Jeffrey M Jacobson, David Zahrieh, Carrie A Strand, et al.
Nature Communications
|
October 4, 2023
PAM-flexible genome editing with an engineered chimeric Cas9
Lin Zhao, Sabrina R T Koseki, Rachel A Silverstein, et al.
The American Journal of Gastroenterology
|
June 24, 2025
Long-Term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results
Cynthia Levy, Palak J Trivedi, Kris V Kowdley, et al.
Journal of Viral Hepatitis
|
March 16, 2013
Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin
G R Foster, S Zeuzem, S Pianko, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
April 6, 2026
Physician Perspectives on Hepatitis C Treatment During Pregnancy: A Multinational Multispecialty Survey
Tatyana Kushner, Maria Buti, Mohamed El-Kassas, et al.
Gut
|
September 13, 2014
Impact of common risk factors of fibrosis progression in chronic hepatitis C
S Rüeger, P-Y Bochud, J-F Dufour, et al.
Lancet (London, England)
|
August 1, 2014
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study
Eric Lawitz, Mark S Sulkowski, Reem Ghalib, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 3, 2023
Interleukin 6 Blockade With Tocilizumab Diminishes Indices of Inflammation That Are Linked to Mortality in Treated Human Immunodeficiency Virus Infection
Nicholas T Funderburg, Carey L Shive, Zhengyi Chen, et al.
Page
of 123
Search research articles
Search
Showing results (1161-1170 of 1,226) with videos related to
Sort By:
Page
of 123
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 1, 2014
Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials
Evguenia S Svarovskaia, Hadas Dvory-Sobol, Neil Parkin, et al.
Lancet (London, England)
|
March 19, 2013
Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial
Kris V Kowdley, Eric Lawitz, Israel Crespo, et al.
Cancer Prevention Research (Philadelphia, Pa.)
|
December 19, 2022
Phase I Trial of a Therapeutic DNA Vaccine for Preventing Hepatocellular Carcinoma from Chronic Hepatitis C Virus (HCV) Infection
Jeffrey M Jacobson, David Zahrieh, Carrie A Strand, et al.
Nature Communications
|
October 4, 2023
PAM-flexible genome editing with an engineered chimeric Cas9
Lin Zhao, Sabrina R T Koseki, Rachel A Silverstein, et al.
The American Journal of Gastroenterology
|
June 24, 2025
Long-Term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results
Cynthia Levy, Palak J Trivedi, Kris V Kowdley, et al.
Journal of Viral Hepatitis
|
March 16, 2013
Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin
G R Foster, S Zeuzem, S Pianko, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
April 6, 2026
Physician Perspectives on Hepatitis C Treatment During Pregnancy: A Multinational Multispecialty Survey
Tatyana Kushner, Maria Buti, Mohamed El-Kassas, et al.
Gut
|
September 13, 2014
Impact of common risk factors of fibrosis progression in chronic hepatitis C
S Rüeger, P-Y Bochud, J-F Dufour, et al.
Lancet (London, England)
|
August 1, 2014
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study
Eric Lawitz, Mark S Sulkowski, Reem Ghalib, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 3, 2023
Interleukin 6 Blockade With Tocilizumab Diminishes Indices of Inflammation That Are Linked to Mortality in Treated Human Immunodeficiency Virus Infection
Nicholas T Funderburg, Carey L Shive, Zhengyi Chen, et al.
Page
of 123